U.S. Markets open in 6 hrs 20 mins

A Look at Athenex’s Research Pipeline

Kenneth Smith
A Look at Athenex’s Research Pipeline

Athenex (ATNX) believes its ability to overcome challenges associated with the oral delivery of chemotherapy and intravenous delivery through its P-gp inhibitor could offer key potential benefits for patients. These developments could help patients stay on therapy longer, extending the potential to combine with other targeted therapies and immunotherapies that would otherwise be too toxic in combination with chemotherapy. Athenex’s orascovery platform is based on the P-gp pump inhibitor molecule HM30181A, which the company had in-licensed from Hanmi Pharmaceuticals in 2011. Coadministering this molecule with oral paclitaxel is designed to facilitate the oral absorption of paclitaxel.